CN119032109A - 用靶向vwf的单特异性抗体治疗血液病症的方法 - Google Patents

用靶向vwf的单特异性抗体治疗血液病症的方法 Download PDF

Info

Publication number
CN119032109A
CN119032109A CN202380034172.8A CN202380034172A CN119032109A CN 119032109 A CN119032109 A CN 119032109A CN 202380034172 A CN202380034172 A CN 202380034172A CN 119032109 A CN119032109 A CN 119032109A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
region
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380034172.8A
Other languages
English (en)
Chinese (zh)
Inventor
亨里克·奥斯特加德
佩拉弗·S·甘地
约翰·H·法伯尔
凯瑟琳·雷
班尼·索伦森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemibo Private LLC
Original Assignee
Hemibo Private LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemibo Private LLC filed Critical Hemibo Private LLC
Publication of CN119032109A publication Critical patent/CN119032109A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380034172.8A 2022-02-15 2023-02-14 用靶向vwf的单特异性抗体治疗血液病症的方法 Pending CN119032109A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263268040P 2022-02-15 2022-02-15
US63/268,040 2022-02-15
US202263269000P 2022-03-08 2022-03-08
US63/269,000 2022-03-08
PCT/EP2023/053681 WO2023156409A1 (en) 2022-02-15 2023-02-14 Methods of treating blood disorders with vwf-targeted monospecific antibodies

Publications (1)

Publication Number Publication Date
CN119032109A true CN119032109A (zh) 2024-11-26

Family

ID=85278579

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380034172.8A Pending CN119032109A (zh) 2022-02-15 2023-02-14 用靶向vwf的单特异性抗体治疗血液病症的方法

Country Status (8)

Country Link
US (1) US20250154283A1 (https=)
EP (1) EP4479435A1 (https=)
JP (1) JP2025507448A (https=)
KR (1) KR20240159860A (https=)
CN (1) CN119032109A (https=)
AU (1) AU2023221511A1 (https=)
CA (1) CA3244108A1 (https=)
WO (1) WO2023156409A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133583A1 (es) * 2023-08-16 2025-10-15 Hemab Aps Métodos para tratar trastornos de la sangre con anticuerpos monoespecíficos dirigidos a vwf
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides

Also Published As

Publication number Publication date
WO2023156409A1 (en) 2023-08-24
KR20240159860A (ko) 2024-11-06
JP2025507448A (ja) 2025-03-18
CA3244108A1 (en) 2023-08-24
AU2023221511A1 (en) 2024-09-12
EP4479435A1 (en) 2024-12-25
US20250154283A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
CA2747519C (en) Anti-fxi antibodies and methods of use
US20220089778A1 (en) Coagulation factor binding proteins and uses thereof
AU2014301041B2 (en) Combination therapy using a Factor XII inhibitor and a C1-Inhibitor
JP2016503400A (ja) 抗補体Ｃ１ｓ抗体とそれらの用途
US20250154283A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
US11542329B2 (en) Antibodies targeting Glycoprotein VI
KR102715492B1 (ko) 인간 혈청 알부민 변이체 및 이의 용도
CN112437682A (zh) 抗因子XII/XIIa抗体和其用途
TW201437229A (zh) 抗活化蛋白ｃ之人化單株抗體及其用途
CN113880949A (zh) 凝血因子xi(fxi)结合蛋白
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
HK40118720A (zh) 用靶向vwf的单特异性抗体治疗血液病症的方法
AU2024324856A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
JP6445440B2 (ja) 抗プロテインｃ抗体による出血性疾患の治療
CN113880950A (zh) 凝血因子xi(fxi)结合蛋白
CN120530134A (zh) 用作凝血剂的抗体
HK40084746A (en) Coagulation factor xi (fxi) binding protein
TW201609808A (zh) 抗活化蛋白ｃ之人類化單株抗體之抗原決定區基因定位及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40118720

Country of ref document: HK